Related Experiment Video

Updated: Jul 25, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Characterization of the activity of alpha/beta-triglycidylurazol (TGU; NSC-332488): a new antineoplastic compound

G Atassi, P Dumont, C Vanhaelen

    European Journal of Cancer & Clinical Oncology
    |September 1, 1984
    PubMed

    Insights

    Alpha/beta-triglycidylurazol (TGU) demonstrates significant antitumour properties against various mouse leukaemias and solid tumours. This compound shows promise for clinical studies due to its efficacy and favorable characteristics.

    Area of Science:

    • Pharmacology
    • Oncology
    • Medicinal Chemistry

    Background:

    • The development of novel anticancer agents is crucial for improving patient outcomes.
    • Identifying compounds with broad-spectrum activity and favorable pharmacokinetic properties is a key research area.

    Purpose of the Study:

    • To evaluate the antitumour efficacy of alpha/beta-triglycidylurazol (TGU) in preclinical mouse models.
    • To assess the activity of TGU against various transplantable tumours, including drug-resistant leukaemias.

    Main Methods:

    • In vivo testing of TGU on established transplantable mouse tumour systems.
    • Assessment of tumour regression and cure rates following TGU administration.

    Main Results:

    • TGU achieved a high cure rate in P388 and L1210 leukaemias.
    • Complete tumour regression was observed for B16 melanoma, colon 38, and RC renal carcinoma.
    • TGU exhibited significant activity against a cyclophosphamide-resistant P388 leukaemia subline.

    Conclusions:

    • Alpha/beta-triglycidylurazol (TGU) possesses potent antitumour activity across multiple preclinical models.
    • Its efficacy against drug-resistant leukaemias and favourable properties (water-solubility, stability) support further clinical investigation.

    More Related Videos

    A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

    A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

    Published on: March 28, 2021

    High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

    High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

    Published on: August 18, 2023

    Related Concept Videos

    TGF - β Signaling Pathway01:16

    TGF - β Signaling Pathway

    The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
    Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

    Adrenergic Agonists: Chemistry and Structure-Activity Relationship

    Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
    Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
    Separation of the aromatic...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...